Form 8-K Arcutis Biotherapeutics, For: Feb 27
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
Arcutis Biotherapeutics Inc. (ARQT) PT Raised to $11 at Goldman Sachs, 'Zoryve launches trending positively'
February 28, 2024 3:31 AM ESTGoldman Sachs analyst Chris Shibutani raised the price target on Arcutis Biotherapeutics Inc. (NASDAQ: ARQT) to $11.00 (from $6.00) while maintaining a Neutral rating.
The analyst comments "ARQT reported 4Q23 results with net Zoryve (roflumilast cream) sales in plaque psoriasis of $13.5mn, above our and Visible Alpha Consensus estimates of... More
